A promising therapeutic approach to cancer was proposed in 2009 by Lubin and Lubin [13], based on the addition of MTA to the treatment of MTAP-negative tumors with toxic purine analogs, like 5-fluorouracil (5-FU). The gene discussed is MTAP; the disease is cancer.